跳至主要内容
临床试验/NCT05945199
NCT05945199招募中不适用

Effectiveness of tDCS on Reducing Craving in Patients Practicing Chemsex: a Single-center, Double-blind, Randomized Controlled Pilot Trial

Centre Hospitalier Universitaire Dijon1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2024年7月29日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
40
试验地点
1
主要终点
Assessment of cue-induced craving for chemsex using a visual analogue scale

研究概览

简要总结

The aim of this research is to evaluate the efficacy of a new treatment for chemsex or "chemical sex", the use of psychoactive substances to modify sexual experience and performance. This treatment, called Transcranial direct current stimulation (tDCS) aims to modulate the cortical activity of brain areas involved in the desire to use psychoactive substances, or drugs, and the desire for uncontrolled sexual intercourse.

This treatment should therefore lead to a reduction in the craving for consumption of psychoactive substances and/or the practice of uncontrolled sexual activity.

The stakes of this new treatment are high, because chemsex exposes people to health risks for themselves and others. These risks include the risk of infection (skin infections, HIV infection, hepatitis viruses), psychological harms (anxiety attacks, depression, suicide risk), risk of addiction (addiction to the psychoactive product used, sex addiction), and toxicological harm (overdose, dangerous combination of psychoactive substances) or trauma (blows, trauma to the genitals or anorectal trauma).

To date, there is no proven therapeutic treatment for people wishing to reduce or stop chemsex.

40 participants will be randomized into 2 groups:

  • 20 patients will receive active stimulation
  • 20 patients will receive sham stimulation

The total duration of the study for each patient will be 13 weeks: 1 week of stimulation and 12 weeks of follow-up.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient who provides written consent
  • Patient aged ≥ 18 years
  • Patient motivated and willing to change chemsex behavior, assessed by examiner during screening and inclusion visits
  • Patient using at least one of the following psychoactive substances to modify sexual performance and/or experience:
  • Cathinones, or methamphetamine, or MDMA, or cocaine, or ketamine, or GBL/GHB
  • ≥ 1 time per month over the past 6 months and/or ≥ 10 times over the past year

排除标准

  • Patient with a substance use disorder not involved in the practice of chemsex
  • Patient with a recent change (< 1 month) in the prescription of a psychotropic treatment
  • Patient presenting an acute psychiatric condition requiring hospitalization and/or immediate modification of a psychotropic treatment
  • Patients with unstable or uncontrolled neuropsychiatric disease
  • Patients with a history of epileptic seizures
  • Patients with unexplained episodes of loss of consciousness, as this condition may be linked to cerebral alterations or epilepsy
  • Patients with advanced or decompensated somatic pathology, requiring hospitalization expected during study follow-up
  • Patients suffering from any serious life-threatening illness, such as congestive heart failure, chronic obstructive pulmonary disease or active neoplasia
  • Patients with implanted cerebral medical devices, implanted pacemakers, or any electrically, magnetically or mechanically activated implant.
  • Patients with cardiac, neural or drug implants
  • Patients with vascular clips or other electrically sensitive support systems in the brain
  • Patients with severe brain lesions
  • Patients with skin lesions at stimulation sites
  • Patients with skin problems such as dermatitis, psoriasis or eczema
  • Patients with severe or frequent headaches
  • Patients who have already benefited from tDCS sessions
  • Pregnant, parturient or breast-feeding women (pregnancy test)
  • Staff working in the addictology department of Dijon University Hospital
  • Patient participating in another clinical trial
  • Patient not affiliated to national health insurance
  • Patient unable to complete assessment scales
  • Patient under psychiatric care without consent or under legal protection (guardianship, curatorship)
  • Major incapable or unable to provide consent

研究组 & 干预措施

Sham tDCS

Placebo Comparator

干预措施: Assessment of risk behaviours (Behavioral)

Sham tDCS

Placebo Comparator

干预措施: Scales (Other)

tDCS active

Experimental

干预措施: tDCS (Device)

tDCS active

Experimental

干预措施: Assessment of risk behaviours (Behavioral)

tDCS active

Experimental

干预措施: Scales (Other)

Sham tDCS

Placebo Comparator

干预措施: tDCS (Device)

结局指标

主要结局

Assessment of cue-induced craving for chemsex using a visual analogue scale

时间窗: 4 weeks from end of stimulation (S5)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Effectiveness of tDCS on Reducing Craving in... | 临床试验